Max Healthcare Institute Limited has reported its financial results for the quarter and year ended March 31, 2026. The company posted a consolidated net profit of 3.4b Rupees for Q4, compared to 3.2b Rupees in the same period last year. Revenue from operations for the quarter stood at 21.4b Rupees versus 19.1b Rupees year-on-year, reflecting steady growth across the hospital network. The board of directors, in its meeting held on May 21, 2026, approved the audited financial results and recommended a final dividend of ₹2 per equity share, subject to shareholder approval. The audio recording of the earnings call held on May 22, 2026, is available on the company's website.

Q4 Financial Performance

The company's operational metrics showed broad-based improvement during the quarter. EBITDA rose to 6b Rupees from 5.1b Rupees in the year-ago period, while EBITDA margin expanded to 28.30% from 26.8%. The following table summarises the key financial highlights for the quarter:

Board Decisions and Dividend

The board approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. Based on the profits for FY26, the directors recommended a final dividend of ₹2 per share, representing 20% of the face value of ₹10 each. The dividend will be paid or dispatched within 30 days from the conclusion of the forthcoming Annual General Meeting (AGM).

Strategic Developments

The board approved an investment of approximately ₹1,400 Cr for the construction of Phase-I of Max Super Specialty Hospital on a 5-acre land parcel at Shaheed Path, Lucknow. The new facility is expected to add approximately 712 beds to the network. The project is proposed to be completed within 36 months from the date of approval of drawings by the UP Awas Avam Vikas Parishad. Additionally, the company completed the acquisition of a controlling stake of 58.28% in Kalinga Hospital Ltd. on May 18, 2026, for an aggregate cash consideration of ₹2,980 Cr, making it a subsidiary.

Operational Highlights

Operational bed capacity as at March 31, 2026, stood at 4,966, reflecting an addition of 412 beds in the last 12 months. Average occupancy was 75%, while outpatient consults grew 8% YoY to 9.2 lakhs. The company also reported significant progress in its brownfield expansion projects, including the commissioning of towers at Max Smart, Mohali, and Nanavati-Max.

Max Healthcare Institute announced that the Competition Commission of India (CCI) has dismissed allegations of abuse of dominant position against its network hospitals. The regulatory body passed separate orders on May 21, 2026, in favour of the company, effectively closing the long-standing proceedings.

The development follows earlier intimations from the company dated August 14, 2023, and March 14, 2025. The case originated from an order dated August 31, 2018, wherein the CCI had directed the Director General (DG) to investigate the healthcare industry regarding the pricing of medicines, packages, and consumables provided by respondent hospitals in Delhi, which included six Max network hospitals.

Regulatory Proceedings and Findings

After the DG submitted its report, the findings were challenged by the respondent hospitals. The CCI subsequently considered a supplementary investigation report filed by the DG, along with the hospitals' objections, oral arguments, and written submissions. Upon review, the Commission rejected the DG's findings related to the alleged abuse of dominance.

The Commission concluded that no case of abuse of dominant position under Section 4 of the Competition Act, 2002, was established against the hospitals. The orders were received by the company on May 21, 2026, at 9:47 PM IST.

Status of Proceedings

The closure of these matters brings a resolution to the regulatory scrutiny faced by the network hospitals. The CCI's decision confirms that the pricing practices investigated did not violate competition laws. The detailed orders are available on the official website of the CCI.